Targeted therapeutics AvidBiotics specializes in protein therapeutics that selectively destroy target cells such as cancer cells and virus-infected cells, presenting a direct outreach angle to oncology and infectious disease segments seeking precision therapies.

Immune activation platform Their platform that activates the immune system to target cancer and viral-infected cells offers collaboration opportunities with immuno-oncology developers and biotech companies seeking immune modulation strategies.

Antibiotic alternatives Development of narrow-spectrum bacteria-killing agents addresses antibiotic resistance and microbiota preservation, appealing to pharma and healthcare organizations pursuing novel antimicrobial solutions and stewardship partners.

Strategic partnerships Past collaborations with Ecolab on antibacterial proteins indicate an openness to industry partnerships across food safety, processing, and public health sectors, suggesting potential co-development or licensing conversations.

Growth and funding signals Revenue in the low-to-mid millions with modest funding suggests a venture-friendly stage suitable for early-stage BD activities, alliance opportunities, and co-development deals to scale platform applications.